secwatch.observer — SEC 8-K summary
======================================

Issuer:     Minerva Neurosciences, Inc. (NERV)
CIK:        0001598646
Form:       8-K
Filed at:   2025-11-19T23:59:59+00:00
Accession:  0001193125-25-287048
Event type: leadership
Sentiment:  positive
Materiality: 0.60
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Minerva Neurosciences appoints Dr. Inderjit Kaul to board; Kaul led Cobenfy schizophrenia program at BMS
--------------------------------------------------------------------------------

- Dr. Kaul appointed to Minerva's board (Class II) effective Nov 14, 2025; board size increased to 6.
- Received initial option grant of 9,500 shares vesting quarterly over 3 years; $40,000 annual cash retainer.
- Consulting agreement: $450/hr for 25-30 hrs/month, six-month term; equity top-ups tied to roluperidone milestones.
- Kaul previously SVP Late-Stage Clinical Development at BMS, led Cobenfy development for schizophrenia; currently CMO of Draig Therapeutics.
- Appointment follows recent $200M private placement to fund confirmatory Phase 3 trial of roluperidone.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1598646/000119312525287048/0001193125-25-287048-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1598646/000119312525287048/d48648d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-287048

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer